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Abstract
Evidence based guidelines exist for sweat testing, which remains a key component of a diagnosis of cystic ﬁbrosis (CF), especially following
newborn bloodspot screening (NBS). There are emerging challenges with respect to maintaining a valid sweat test service, notably a smaller
number of sweat tests ordered in regions with established NBS programmes where Pediatricians refer less children for sweat testing, younger
patients and equipment becoming obsolete. The ECFS Diagnostic Network Working Group has undertaken a comprehensive survey to better
deﬁne sweat test practice across Europe. The survey was completed by 136 European respondents representing a CF center or laboratory providing
a sweat test service (65% from regions with NBS for CF). There was considerable variance in practice, often not consistent with guidelines. In
particular collection of sweat from two sites was rarely reported in European centres in contrast to US guidelines. There was a range of different
references quoted for cut-off for both a positive and intermediate test. Most responses suggest cost is becoming an increasing issue and is not
sufﬁciently reimbursed. This work will inform best practice guidelines and resources to sustain and improve sweat testing in Europe.
© 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
The diagnosis of cystic fibrosis (CF) is made with one of the
following presentations: characteristic clinical features, a family
history of CF or a positive antenatal or newborn bloodspot
CF screening (NBS) result. Confirmatory diagnostic tests are
required and these should always include a sweat test, even
when two CF causing mutations are identified of the Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR) gene
[1–2]. Recent international consensus guidelines reduced the
upper cut-off value for a normal sweat chloride to 30 mmol/L
for all ages [1].
The sweat test requires experienced staff who can follow
standard operating procedures. There are clear national and
international guidelines available for laboratories providing
a sweat test service [3–6]. For most people with CF the
diagnosis is straightforward and the sweat test demonstrates
the characteristically raised salt levels in the sweat (chloride
being the most repeatable and reliable diagnostic measure) [7].
For some patients the diagnosis is less clear and in these cases,
the sweat test result is important in guiding designation and
management [8–10]. Moreover, recently published guidelines
have changed the borderline cut-off chloride values to 30 mmol/L
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for all ages [1]. The sweat test also has a key role in the exclusion
of a diagnosis of CF, given the extensive number of recognised
CFTR mutations and the possibility of detecting new CFTR
mutations. As such, sweat testing is a critical element of the
follow-up of a positive newborn screening result, irrespective of
the screening algorithm employed [11].
Providing a sweat test service has become increasingly
challenging, particularly in regions that undertake NBS for
CF. In these regions referrals for sweat testing are decreasing
and those referred after NBS are by definition younger than
3 months of age [12]. In addition, equipment that has been used
by many laboratories for decades is now becoming obsolete
and commercially available systems have cost and training
implications.
Results from different national CF registries in Europe
demonstrate the significant number of patients with CF, who
have either missing sweat test documentation or misdiagnosis of
CF as a result of inadequate performance and false interpretation
of sweat test [13–14]. Surveys conducted at national level have
shown that monitoring the performance of laboratories and CF
centres together with quality improvement initiatives improves
the performance of sweat testing [15–17].
The aim of this project was to record current sweat test
practice among Europe, to inform the requirements and contents
of a future best practice document.
2. Methods
The questionnaire for the survey was developed by a core
group of experts, referring to international guidelines and tested
by another panel of experts (from the European CF Society
(ECFS) Diagnostic Network and Neonatal Screening Working
Groups). The questionnaire comprised 66 items covering six
areas; 1) CF centre/laboratory details, 2) information provided
to patient/parent/carers, 3) the method of sweat stimulation,
4) the method of sweat collection, 5) sweat analysis and
6) processing of the result. The questionnaire was in English,
web-based and open from 15th October to 15th December 2015
to ECFS members, Cystic Fibrosis Europe members, national
CF scientific societies and national sweat test working groups.
Information on the project was disseminated several times and
a help desk was established to assist participants, in particular
with language issues. For three questions, there was overlap
of potential responses, but respondents did not comment on
this design error and the results were considered valid, as the
questions were enquiring about approximate numbers (Table S1).
CF centres and laboratories were asked to send a scanned
anonymised copy of their sweat test report sheet and the infor-
mation leaflet (if available) for patients/parent/carers. Although
informative responses were obtained from all over the globe
(n = 143), only results from Europe (and Israel) were included
in the analysis (n = 136). For the four countries with the highest
number of respondents, the results were compared as a proportion
of responses from each country (France, Germany, Italy and the
United Kingdom). (Table 1).
3. Results
The survey was completed by 136 European sites across
29 countries (Fig. 1). For 127, the response jointly represented
a CF centre and sweat test laboratory, for 8 a CF centre only
and one respondent a laboratory only. The full questionnaire
with responses is available (online Supplement Table S1) and
the main findings are reported in this paper.
3.1. Institution and staff involved in test
Respondents represented CF centres of variable size and
laboratories. The sweat test service was provided in a region
with NBS for CF in the majority of respondents (65%).
Sweat stimulation and collection was undertaken by laboratory
technicians (49%), nurses (45%) and physiotherapist, physician,
biologist and other laboratory staff (6%), most in a permanent
employment (90%). Most respondents (72%) had considerable
experience (N100 tests/year), although 42% reported undertaking
b25 sweat tests pa/annum on infants with a positive NBS result.
Nineteen percent indicated the cost of a sweat test (including
staff) was less 20 Euros, for 30% between €20 and 50, for 26%
Table 1
Comparison of selected data from most represented countries (sites/country n=: France, 19; Germany, 25; Italy, 15; United Kingdom, 22).
Proportion of centres that: France (%) Germany (%) Italy (%) United Kingdom (%)
Are certified 100 88 80 86
Perform N100 tests per year 58 96 93 36
Have dedicated staff performing N30% of the total tests/year 53 72 87 68
Sweat test newborn screened babies 95 48 80 73
Report costs (including staff) b20 Euros 26 4 13 5
Receive reimbursement b20 Euros 58 56 67 5
Undertake bilateral testing 37 0 40 9
Use Wescor sweat inducer to stimulate sweat production 37 60 80 73
Collect sweat using a macroduct coil 37 84 13 82
Have a quantity not sufficient rate b5% in all ages 68 56 47 41
Have a quantity not sufficient rate b5% for infants b1 month of age 37 32 40 41
Use internal quality control as recommended 84 64 67 86
Participate in an external quality assurance scheme 74 24 44 46
Use b30 mmol/L as lower cut-off for normal sweat chloride 47 84 20 9
Use N60 mmol/L as the cut-off for a positive sweat chloride result 74 64 87 96
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between€50 and 100, for 11% between 100 and 300 Euros and
for 14% total reimbursement was reported as unknown or absent.
Sweat test reimbursement was reported as below €20 in 37%
of participating sites (online Supplement Fig. S1). There was no
reported difference in cost between regions with and without
NBS programs.
3.2. Information for patient/parent/carers
Information about the sweat test performance was provided
for patient/parent/carers in 95% cases (written information in
43%). The information was provided by the person collecting
the sweat in 41%. In a small number (9%) informed consent
was also taken.
3.3. Sweat stimulation by iontophoresis
The majority of respondents (51%) reported that sweat
stimulation and collection was only undertaken from one site.
Sweat stimulation was routinely undertaken on two different
skin areas in 18% (7 sites from France, 5 from Italy, 4 from
Belgium, 3 from UK, 1 from Denmark, 1 from Russia, 1 from
Serbia, 1 from Spain, 1 from Switzerland,) and under special
circumstances in 31% (for example, after a positive NBS result,
if the distance travelled was far or if a previous sample was
insufficient). The flexor surface of the forearm was the most
common region chosen to stimulate sweat production (91%).
Most services used a commercially available system to stimulate
sweat production (70%). The lowest insufficient tests (QNS)
rate in all ages was achieved with the Webster™ system (b5%
QNS = 72%) and the lowest QNS rate for infants under 1 month
of age with the Wescor™ sweat inducer (b10% QNS = 33%).
Centres in regions with NBS program reported higher QNS rates
compared to centres in regions without NBS program (b5%QNS
in all ages: 56% vs 64%). Surfaces and equipment were correctly
cleaned between each subject in 56% [18–19].
3.4. Sweat collection
Commercially available capillary tubes were used by 56% of
respondents, only 48% for the recommended time of 30 min,
4% b20 min; 24% 20–30 min; 15% 30–45 min; 5% 45–
60 min; 2% until Macroduct coil is full; 2% 35 min. For those
respondents, 41% reported storing the pure sweat liquid
collected in the capillary tube (either in the tubing or a sealed
laboratory tube) and 50% reported that the sample was analyzed
immediately. 95% of respondents reported a minimum age
(range, 2–42 days) and/or a minimum weight (2–3.5 kg) below
which they would not attempt sweat collection.
3.5. Sweat analysis
Analysis of samples was performed by laboratory staff in
85% (12% clinical staff; 3% other (biologist, physiotherapist,
nurse) and 52% reported involvement with an external
quality assurance scheme. For measurement of chloride from
a liquid sample, the most reported method was coulometry
using a chloridometer (54%). 68% of respondents reported
only analyzing for sweat chloride, 16% for conductivity only
and 16% for both.
Fig. 1. Country distribution of participants in the ECFS diagnostic network working group sweat test survey 2015 (total n = 136).
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3.6. Inadequate sample collection and repeat testing
81% of respondents described performing at least a second
sweat test to confirm a CF diagnosis (8% on the same day,
range 1–28 days). For 43% the minimal acceptable volume for
chloride analysis was reported as 20 µL: this is the minimum
acceptable volume for the Macroduct™ conductivity method
and for the analysis of chloride in undiluted sweat. 60% of the
sites reported a failure rate (i.e. low sweat volume, quantity not
sufficient) below 5% for all tested persons, although 38% for
newborns (b1 month).
In the case of an insufficient sweat volume, sweat collection
is repeated at another time in 77% of the cases (in 76% on
another day).
3.7. Processing a sweat test result
Reference ranges quoted for interpretation of a sweat test
result were variable. For the CF centres/laboratories that
measure sweat chloride, only 18% reported using a different
reference range for infants below 6 months of age. 60% sites
used chloride negative range b30 mmol/L (29% of which used
b40 mmol/L above 6 months of age); 53% sites used chloride
intermediate range 30–59 mmol/L (22% of which used 40–
59 mmol/L above 6 months of age); 68% sites used chloride
positive range N60 mmol/L for all ages. In total, 12 different
cut-offs for sweat chloride concentration were reported, ranging
from b20 mmol/L to 50 mmol/L for a negative result and from
20 mmol/L to 90 mmol/L for an intermediate result. Variability
for the reference ranges of other analytes (sodium, conductivity,
osmolality) was more marked. A negative sweat test result is
reported as “CF unlikely” by 74% of respondents, an intermediate
result as “need for repeat sweat test” by 81% and a first positive
result as “CF likely” which needs to be repeated” by 63%. All
CF centres or laboratories used a written sweat test report. In
most cases the diagnosis of CF was reported by a specialist
doctor (87%).
Data from France, Germany, Italy and United Kingdom
demonstrates some variation in approach of these countries
(Table 1).
4. Discussion
This survey of real life practice across Europe provides
evidence to support concerns around the increasing challenge
of providing a high quality sweat service [9]. One of the main
factors, the expansion of NBS for CF across Europe, has resulted
in an overall change in referrals for sweat testing, alongside
the challenge of collecting sweat from smaller infants [8]. For
respondents providing a sweat test service in a screening area, the
majority reported undertaking b50 sweat tests annually, which
makes maintaining a high quality service difficult.
The country distribution of participants overall reflected
the present situation of European sites providing CF care. We
identified considerable variance in all aspects of the sweat test,
from stimulation and collection, to analysis and how the result
is communicated. Most notable was the variance with respect
to obtaining sweat from two skin sites during a single test.
Collecting from two sites is a clear recommendation from US
guidelines but less so from European, where the circumstance of
the sweat test is often stated as a factor [2–5]. A proportion of
respondents stated that two collections would only be undertaken
in special circumstances, for example if the family had travelled a
long distance or the infant was particularly small. Some [20] but
not all [21] retrospective data suggest that collection from two sites
may reduce the “quantity not sufficient” test results, but given the
time and resource implications of this strategy prospective studies
are required to better determine the validity of this strategy.
Some of the variance identified reflects the development
and evolution of sweat test techniques over the past 40 years.
As equipment for the filter paper based collection techniques
becomes obsolete, most units are moving to commercially
available systems to collect sweat in a capillary tube. Such
systems have facilitated more consistent standard operating
procedures but this survey suggests that there continues to be
variance in stimulation, collection times and processing (online
Supplement Table S1). The move to commercially available
kits has cost implications and this is illustrated by the survey,
highlighting that reported costs are variable, but a significant
factor for most.
Data from the four most represented countries demonstrate
significant inconsistencies in approach despite national recom-
mendations and regular audits (Table 1). Cost and insufficient
reimbursement were repeatedly reported as factors influencing
choice of equipment. These data can only partially explain
differences within the most represented countries but can
represent the basis for local audits.
The survey illustrates differences in processing and evalu-
ation of results, with variance in the reference ranges employed
and interpretation of guidelines. This highlights the need for
more consistent global guidelines. Recent international initia-
tives on diagnostic recommendations will hopefully clarify
this situation [1,22–23]. Measurement of conductivity is still
regularly undertaken, despite being recommended only as a
screening tool to exclude CF [3,24–26]. Most centres report
subsequent analysis of sweat chloride in a laboratory to confirm
a diagnosis. An important limitation of the survey design is
represented by partially overlapping categories in 3/66 answers
(sweat test cost and reimbursement, sweat collection time):
having the same values for various categories, which is confusing
even if the respondents are being asked for an estimate.
Although this survey illustrates considerable variance in
practice and some areas of concern, it is apparent that excellent
practice is somewhere achieved (existence of national recom-
mendations, high rate of centres participating in an external
quality assurance scheme, high rate of adherence to interna-
tional sweat test recommendations and regular national sweat
test auditing) and many resources have been developed across
Europe to support the provision of a high quality service and
clear communication with families. It is important that we utilise
these resources and make them available in order that good
practice is disseminated across Europe. We need to be able to
address the challenges of maintaining high quality sweat test
services by adopting a consistent and pragmatic approach.
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